Q6GMX6 (Q6GMX6_HUMAN) Homo sapiens (Human)
IGH@ protein UniProtKBInterProInteractive Modelling
465 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
32 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| The structure of an antitumor CH2-domain-deleted humanized antibody |
Heteromer | 40.0 | ||||
| RSV-neutralizing human antibody AM22 |
Heteromer Q8TCD0; | 43.14 | 17×EDO; | |||
| Trastuzumab Fab v3 with 5-diphenyl meditope variant |
Heteromer P01834; P02976; Q51918; | 77.63 | ||||
| Antibody structural organization: Role of kappa - lambda chain constant domain switch in catalytic … |
Heteromer A2NUT2; | 92.69 | 1×MES; | |||
| Trastuzumab Fab v3 in complex with 5-phenyl meditope variant |
Heteromer P01834; P02976; Q51918; | 77.63 | ||||
| CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB |
Heteromer Q6P5S8; | 73.24 | ||||
| Human IL-2/Fab complex |
Heteromer P60568; Q6IPQ0; | 93.15 | 1×GOL; | |||
| SARS-CoV-2 Delta-RBD complexed with BA.2-36 Fab |
Heteromer A0A8B6RM54; P0DOX7; | 89.95 | 1×NAG; | |||
| human Fab 5H2 bound to NHBA-C3 from Neisseria meningitidis serogroup B |
Heteromer Q6GMX0; Q9JPP1; | 90.87 | 2×EDO; | |||
| RSV prefusion F in complex with AM22 Fab |
Heteromer P03420; Q8TCD0; | 43.14 | 3×NAG; 3×CD; 6×PEG; | |||
| Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425 |
Heteromer A0A0B4J1V1; P03420; P0DOX5; Q6GMX4; Q8TCD0; | 43.14 | ||||
| Humanized antibody 4B12 Fab complexed with a CemX segment |
Heteromer Q0KKI6; | 90.61 | ||||
| CH1/Ckappa Fab based on Matuzumab |
Heteromer Q7Z3Y4; | 75.23 | ||||
| I3.2 (unbound) from CH103 Lineage |
Heteromer | 88.99 | ||||
| I3.1 (unbound) from CH103 Lineage |
Heteromer | 88.68 | ||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B9 |
Heteromer A0A5C2G1U0; P01825; P0DTC2; Q8TCD0; | 100 | 19×NAG; 33×NAG; | |||
| Crystal structure of germline Fab PGT121, a putative precursor of the broadly reactive and potent H… |
Heteromer | 45.45 | 2×GOL; | |||
| I33M (I3.2 mutant from CH103 Lineage) |
Heteromer Q8N355; | 88.63 | 1×CL; | |||
| Fab structure of anti-HIV-1 gp120 V2 mAb 697 |
Heteromer Q6GMX4; | 74.19 | ||||
| Crystal structure of isolated domain III of the extracellular region of the epidermal growth factor… |
Heteromer P00533; | 90.1 | 1×NAG; 1×NAG; 2×NAG; 1×SO4; | |||
| I2 (unbound) from CH103 Lineage |
Heteromer | 84.79 | ||||
| Crystal structure of ABT-007 FAB fragment with the soluble domain of EPO receptor |
Heteromer P19235; Q7Z3Y4; | 93.55 | ||||
| Crystal structure of the extracellular region of the epidermal growth factor receptor in complex wi… |
Heteromer P00533; | 90.1 | 1×NAG; 2×NAG; 2×NAG; | |||
| CH1/Ckappa Fab mutant 15.1 |
Heteromer Q7Z3Y4; | 73.61 | 5×SO4; 4×EDO; | |||
| Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 FP-MPER H… |
Heteromer | 73.79 | 2×SO4; 1×GOL; | |||
| Crystal Structure of Germline Antibody PGT121-GL Fab |
Heteromer Q8N355; | 93.84 | ||||
| UCA (unbound) from CH103 Lineage |
Heteromer | 95.73 | ||||
| Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex |
Heteromer P01834; P04626; P0DOX5; | 78.24 | 1×NAG; 5×NAG; | |||
| ANTIBODY TO CAMPATH-1H HUMANIZED FAB |
Heteromer Q6GMX0; | 85.85 | ||||
| S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 |
Heteromer A0A5C2GCZ2; A0A5C2GF00; P0DTC2; Q8TCD0; | 100 | 21×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; P0DTC2; Q8TCD0; | 100 | 20×NAG; 30×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; P0DTC2; Q8TCD0; | 100 | 20×NAG; 31×NAG; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7czx.1.D | monomer | 0.73 | 96.86 | |||